JP2005047907A - Antiinflammatory/analgesic composition for external use - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a highly effective antiinflammatory/analgesic composition for external use by increasing skin permeability of a nonsteroidal antiinflammatory/analgesic agent. <P>SOLUTION: This antiinflammatory/analgesic composition for external use contains the nonsteroidal antiinflammatory/analgesic agent and light anhydrous silicic acid. Nonsteroidal antiinflammatory/analgesic agents are used for chronic rheumatism, osteoarthritis and acute and chronic musculoskeletal pains but generally have a side effect such as gastrointestinal injury. Therefore, various formulations other than oral agents such as external preparations and suppositories have been developed and used for medical practice. The present invention solves the problem associated with the external preparations wherein satisfactory effects could not be achieved due to a marked deterioration in the skin permeability of the drug induced by a biological barrier effect of keratin. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to an external anti-inflammatory analgesic composition having an increased skin permeability of medicinal ingredients.

  Non-steroidal anti-inflammatory analgesics are used for rheumatoid arthritis, osteoarthritis, musculoskeletal acute and chronic pain, and the like. However, since it generally has side effects such as gastrointestinal disorders, various dosage forms such as external preparations and suppositories have been developed in addition to oral preparations and have been used in the medical field. However, in the case of an external preparation, since the skin permeability of the drug is remarkably suppressed by the effect of the biological barrier due to the keratin, there are cases where a satisfactory effect cannot be obtained.

  Conventionally, a percutaneous absorption enhancer has been studied in order to increase the skin permeability of a drug. For example, nicotinic acid ester (patent document 1), lactic acid and polyoxyethylene alkyl ether phosphate and lauric acid diethanolamine salt (patent document 2), ethylene oxide addition type nonionic surfactant (patent document 3), polyoxy Ethylene alkyl ether agents and polyoxyethylene phenyl ether agents (Patent Document 4), 1- [2- (decylthio) ethyl] azacyclopentan-2-one and cyclodextrins (Patent Document 5), polyoxyethylene derivatives and polyethylene Glycol (Patent Document 6), polyethylene glycol stearate ester or polyoxysorbitan stearate ester (Patent Document 7), alkylene glycol derivative, 1-alkylazacycloheptan-2-one, fatty acid and derivatives thereof, fatty acid alkanolamide Class And polyethylene glycol derivatives (Patent Document 8), epezoline or tolperisone (Patent Document 9), 1-alkylazacycloheptan-2-one and cis-olefin compounds (Patent Documents 10 and 11), N-substituted morpholine (Patent Document 12) ) And absorption accelerator blending techniques such as oleates (Patent Document 13) are disclosed.

  In addition, a percutaneous absorption enhancer containing a powder that increases the longitudinal relaxation time of the NMR spectrum of the oil as an active ingredient is also known (Patent Document 14).

  However, when these percutaneous absorption enhancers are blended, adding a sufficient amount of the percutaneous absorption enhancer to produce an effect is still satisfactory because it tends to cause skin irritation and the effect is insufficient. It was not possible.

  Furthermore, a skin-type external preparation for skin application is disclosed in which a relatively large amount of a polyhydric alcohol, a polymer compound and solid particles are blended in the preparation to enhance the feeling of use (Patent Document 15). However, this technique is troublesome because it requires rubbing after application, and has a drawback that if it is not wiped off after application, it will stain the clothes.

  Further, an external preparation is disclosed in which the percutaneous absorbability of the drug is enhanced by blending scrub (Patent Document 16). However, this technique has a problem that the scrub is a particulate matter that peels off the stratum corneum of the skin or causes minute scratches, so that it is likely to cause skin irritation and the feeling of use is poor.

JP 61-27920 JP 5-186371 JP-A-6-279289 JP 58-79918 JP 4-275235 JP 4-103528 JP 10-87494 A Special table flat 8-500365 JP2000-143510 7-57725 7-68147 JP 2-59528 JP-A-63-313731 JP-A-11-189545 JP2003-81881 JP-A-11-80031

  An object of the present invention is to provide an external anti-inflammatory analgesic composition that exhibits an excellent effect by increasing the skin permeability of a non-steroidal anti-inflammatory analgesic.

  As a result of intensive studies to solve such problems, the present inventors have found that the addition of certain powder components in the composition increases the skin permeability of non-steroidal anti-inflammatory analgesics. Completed the invention.

  That is, this invention is a non-steroidal anti-inflammatory analgesic and an external anti-inflammatory analgesic composition characterized by containing a light silicic acid anhydride.

  According to the present invention, it is possible to provide an external anti-inflammatory analgesic composition in which the skin permeability of a non-steroidal anti-inflammatory analgesic is increased.

  Nonsteroidal anti-inflammatory analgesics effective in the present invention are indomethacin, piroxicam, ampiroxicam, meloxicam, lornoxicam, suprofen, bufexamac, bendazac, ufenamate, ketoprofen, ibuprofen, ibuprofen piconol, flurbiprofen, naproxen, loxoprofen , Aluminoprofen, felbinac, diclofenac sodium, sulindac, flufenamic acid, mefenamic acid, tolfenamic acid, glycyrrhetinic acid and salts thereof, glycyrrhizic acid and salts thereof, glycolic salicylate, methyl salicylate, etc., with indomethacin or piroxicam being particularly preferred .

  In the present invention, the blending amount of the non-steroidal anti-inflammatory analgesic is preferably 0.1 to 20% by mass, more preferably 0.5 to 5% by mass based on the entire preparation. However, it can be appropriately changed depending on the dosage form and the type and amount of the nonsteroidal anti-inflammatory analgesic.

  Although there is only one kind of silicic acid anhydride in terms of chemical formula, there are different kinds in terms of particle size, specific volume or thixotropy. The silicic anhydride used in the present invention is particularly light.

  Although the mechanism of action for promoting percutaneous absorption of the present invention is unclear, use of zinc oxide having a skin astringent action significantly suppresses percutaneous absorption. It is considered to be specific to the combination of silicate and light anhydrous silicic acid.

  In the present invention, the blending amount of light anhydrous silicic acid is preferably 0.1 to 10% by mass, and most preferably 0.1 to 7% by mass, based on the entire preparation.

  If it is less than 0.1% by mass, the effect of promoting non-steroidal anti-inflammatory analgesic skin absorption will be insufficient, and if it is 10% by mass or more, the properties of the preparation will be greatly affected and the feeling of use will be reduced. is there.

  The average particle size of the light anhydrous silicic acid used in the present invention is preferably 0.001 to 100 μm, and most preferably 1 to 50 μm. The light anhydrous silicic acid is preferably finer, but fine particles of 0.001 μm or less are difficult to produce, and if it is 100 μm or more, a rough feeling may occur after the formulation is applied.

  In the present invention, there is no particular need for rubbing, and skin absorption is promoted.

  The anti-inflammatory analgesic composition for external use of the present invention can be prepared as a liquid preparation such as cream, ointment, lotion, semi-solid preparation such as gel, aerosol, tick, etc. The gel is most preferred from the standpoint of maintaining a uniform and a feeling of use. These can be produced by conventional methods.

  Here, the gel agent is a commonly used gelling agent (alginic acid, propylene glycol alginate, ethyl cellulose, methyl cellulose, carboxyvinyl polymer, acrylic acid / alkyl methacrylate copolymer, carbomer, carboxymethyl cellulose, xanthan gum, carrageenan, hydroxy Propylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, aluminum stearate, dextran fatty acid ester, salts and derivatives thereof, etc. can be used Preferred from the properties of the gel are carboxyvinyl polymer, alkyl-modified carbo One or more selected from the group consisting of civinyl polymer, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose or a salt thereof, alginic acid or a salt thereof, xanthan gum and carrageenan Among these, one or more selected from carboxyvinyl polymer, hydroxypropylmethylcellulose, hydroxyethylcellulose and hydrophobized hydroxypropylmethylcellulose are most preferable.

  Moreover, when mix | blending a polyhydric alcohol with the anti-inflammatory analgesic composition for external use of this invention, the compounding quantity has preferable 20 mass% or less of the whole preparation. This is because when it exceeds 20% by mass, not only the feeling when applied but also the clothes, bedding, etc. are soiled if not wiped off after being applied to the skin.

  The viscosity of the gel used for producing the gel preparation in the present invention is preferably 30 mPa · s to 5000 mPa · s, and most preferably 100 mPa · s to 500 mPa · s in view of the usability such as ease of application.

  Although liquid preparations can also be prepared according to conventional methods, for example, after dissolving a non-steroidal anti-inflammatory analgesic in a liquid such as a lower alcohol, a polyhydric alcohol, water or a mixed solution thereof, light anhydrous silicic acid is dispersed. Can be obtained. When an appropriate gelling agent is blended with the liquid obtained here, a gel can be obtained. The light anhydrous silicic acid may be added before or after the gelling agent is added.

It is preferable from the viewpoint of medicinal effect that the anti-inflammatory analgesic composition for external use of the present invention contains a drug capable of improving symptoms such as rheumatoid arthritis, osteoarthritis and musculoskeletal acute / chronic pain in addition to the ingredients. Examples of such drugs include camphor, turpentine oil, mint oil, menthol and derivatives thereof, eucalyptus oil, refreshing agents such as menthyl lactate, local irritants such as nonylic acid vanillylamide and capsaicin, anti-inflammatory agents such as glycyrrhizic acid, Diphenylimidazole, diphenhydramine and its salts, antihistamines such as chlorpheniramine maleate, blood circulation promoters such as tocopherol acetate and benzyl nicotinate, arnica tincture, agaric extract, sushi extract, horse chestnut extract, funnel extract, belladonna extract, toki extract, Herbal medicines such as coconut extract, salamander extract, and pepper extract are listed.

  In the external anti-inflammatory analgesic composition of the present invention, various base components that can be blended with pharmaceuticals and quasi-drugs can be blended within a range that does not impair the effects of the present invention.

  Hereinafter, the present invention will be described in more detail with reference to examples and test examples.

Example 1: 0.5 g of gel piroxicam
Ethanol 30g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount light silicic acid 7.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, add propylene glycol, add an ethanol solution in which piroxicam is dissolved, add a pH adjuster, mix uniformly, and then add light anhydrous silicic acid dispersed in ethanol. In addition, the gel was obtained by mixing so as to disperse uniformly.

Example 2: Gel agent piroxicam 0.5 g
l-Menthol 3.0g
Ethanol 45g
1,3-butylene glycol 10g
Carboxy vinyl polymer 0.5g
Hydroxypropyl methylcellulose 0.5g
pH adjuster Appropriate amount of light anhydrous silicic acid 0.5g
100g of purified water
A carboxyvinyl polymer and hydroxypropylmethylcellulose were swollen in purified water, 1,3-butylene glycol was added, and an ethanol solution in which a pH adjuster, piroxicam, and 1-menthol were dissolved was added and mixed uniformly. Further, light anhydrous silicic acid dispersed in ethanol was added and mixed so as to be dispersed uniformly to obtain a gel.

Example 3: Gel Indomethine 1.0 g
Ethanol 40g
Propylene glycol 15g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount light anhydrous silicic acid 5.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, propylene glycol was added, and a pH adjuster dissolved in purified water was added to cause gelation. A separately prepared ethanol solution in which indomethacin was dissolved was added and mixed to be uniform, and then light anhydrous silicic acid dispersed in ethanol was added and mixed to be uniformly dispersed to obtain a gel.

Example 4: Gel agent indomethacin 1.0 g
Ethanol 70g
1,3-butylene glycol 5g
Carboxyvinyl polymer 1.0g
pH adjuster appropriate amount light anhydrous silica 3.0g
100g of purified water
After swelling the carboxyvinyl polymer in purified water, 1,3-butylene glycol was added, and a pH adjuster dissolved in purified water was added to cause gelation. A separately prepared ethanol solution in which indomethacin was dissolved was added and mixed to be uniform, and then light anhydrous silicic acid dispersed in ethanol was added and mixed to be uniformly dispersed to obtain a gel.

Example 5: 0.5 g cream piroxicam
Tocopherol acetate 0.5g
l-Menthol 3.0g
dl-Camphor 0.5g
Light anhydrous silicic acid 5.0g
Glycerin 5.0g
Polysorbate 60 2.5g
1,3-butylene glycol 10.0g
Liquid paraffin 4.0g
Squalane 4.0g
Cetostearyl alcohol 5.0 g
Benzyl alcohol 1.0g
Stearic acid 1.0g
Stearic acid monoglyceride 1.5g
Carboxy vinyl polymer 0.2g
Xanthan gum 0.1g
Dimethylpolysiloxane 0.5g
pH adjuster
L-Arginine Appropriate amount edetate salt Appropriate amount of parabens Appropriate amount Sodium pyrosulfite Appropriate amount of purified water 100g
Carboxyvinyl polymer and xanthan gum were dissolved in purified water, a drug dissolved in an aqueous component was added, and the mixture was heated to 80 ° C. while stirring with a tabletop emulsifier. An oily component that had been heated and melted in advance was added thereto from the hopper and cooled to 50 ° C. After homogenizing at 8000 rpm for 3 minutes and homogenizing, light anhydrous silicic acid dispersed in an aqueous component was added from a hopper and cooled to room temperature while stirring with a scraping mixer. Finally, a pH adjusting agent was added and gelled to prepare a cream.

Example 6: 0.5 g cream piroxicam
Tocopherol acetate 0.5g
l-Menthol 3.0g
dl-Camphor 0.5g
Light anhydrous silicic acid 5.0g
Propylene glycol 10.0g
Sorbitan monostearate 4.0g
Polysorbate 60 6.0g
Liquid paraffin 30.0g
Isopropyl myristate 4.0g
Cetostearyl alcohol 6.0g
Benzyl alcohol 3.0g
Xanthan gum 0.1g
Dimethylpolysiloxane 0.5g
Dibutylhydroxytoluene 0.1g
L-Arginine Appropriate amount edetate salt Appropriate amount of parabens Appropriate amount Sodium pyrosulfite Appropriate amount of purified water 100g
Xanthan gum was dissolved in purified water, a drug dissolved in an aqueous component was added, and the mixture was heated to 80 ° C. while stirring with a desktop homomixer. An oily component that had been heated and melted in advance was added thereto from the hopper and cooled to 50 ° C. After homogenization at 8000 rpm for 3 minutes and homogenization, light anhydrous silicic acid dispersed in an aqueous component was added from a hopper, and cooled to room temperature while stirring with a scraping mixer to prepare a cream.

Example 7: Gel agent indomethacin 1.0 g
l-Menthol 3.0g
Light anhydrous silicic acid 2.0g
Octyldodecyl myristate 5.0g
Sorbitan monostearate 1.0g
Polysorbate 60 2.0g
Glycerin monostearate 2.0g
Diisopropyl adipate 3.0g
Hydroxypropyl methylcellulose 0.5g
Carboxy vinyl polymer 0.5g
Isopropanol 36g
Edetate appropriate amount sodium bisulfite appropriate amount pH adjuster appropriate amount purified water 100g
Carboxyvinyl polymer, hydroxypropyl methylcellulose was swollen in purified water, heated to 80 ° C. with stirring, oily components and drugs that had been preheated and melted were added from the hopper, and cooled to 50 ° C. . After adding aqueous components and homogenizing, light anhydrous silicic acid dispersed in isopropanol was added from a hopper, cooled to room temperature while stirring with a scraping mixer, and finally a pH adjuster was added to prepare a gel. .

Example 8: Lotion agent Piroxicam 0.5g
l-Menthol 3.0g
Tocopherol acetate 0.5g
dl-Camphor 0.5g
Light anhydrous silicic acid 1.0g
1,3-Butylene glycol 5.0g
Benzyl alcohol 1.0g
Purified water 20.0g
Polysorbate 80 2.0g
Sodium bisulfite Appropriate edetate Appropriate dibutylhydroxytoluene Appropriate ethanol Total 100 mL
Among the above components, components other than light anhydrous silicic acid were stirred and dissolved uniformly, and then light anhydrous silicic acid was added to prepare an external solution.

Example 9: Lotion preparation Piroxicam 0.5 g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Light anhydrous silica 3.0g
1,3-Butylene glycol 5.0g
Benzyl alcohol 1.0g
Purified water 20.0g
Polysorbate 80 2.0g
Sodium bisulfite appropriate amount edetate appropriate amount dibutylhydroxytoluene appropriate amount ethanol 20mL
100 ml of isopropanol
Among the above components, components other than light anhydrous silicic acid were stirred and dissolved uniformly, and then light anhydrous silicic acid was added to prepare an external solution.

Example 10: Lotion agent Piroxicam 0.5 g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Light anhydrous silicic acid 5.0g
Purified water 20.0g
Polysorbate 60 1.0g
Sodium bisulfite Appropriate edetate Appropriate dibutylhydroxytoluene Appropriate ethanol Total 100 mL
Among the above components, components other than light anhydrous silicic acid were stirred and dissolved uniformly, and then light anhydrous silicic acid was added to prepare an external solution.

Example 11: Gel Agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropyl methylcellulose to the lotion obtained in Example 8, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 12: Gel Agent A gel agent was prepared by further adding 0.5 g of carboxyvinyl polymer and 1.0 g of hydroxypropylmethylcellulose to the lotion obtained in Example 8 and dissolving it, and then adding an appropriate amount of a pH adjuster.

Example 13: Gel Agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 9, the gel agent was prepared by adding an appropriate amount of a pH adjuster.

Example 14: Gel Agent A gel agent was prepared by further adding 1.0 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 9 and dissolving it, and then adding an appropriate amount of a pH adjuster.

Example 15: Gel Agent After adding 0.5 g of carboxyvinyl polymer and 0.5 g of hydroxypropylmethylcellulose to the lotion obtained in Example 10, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 16: Gel agent After adding 0.5 g of carboxyvinyl polymer and 1.0 g of hydroxypropylmethylcellulose to the lotion obtained in Example 10, the gel was prepared by adding an appropriate amount of a pH adjuster.

Example 17: Gel Agent A gel agent was prepared by further adding 1.0 g of hydroxyethyl cellulose to the lotion obtained in Example 8 and dissolving it.

Example 18: Gelling agent To the lotion obtained in Example 10, 1.0 g of hydrophobized hydroxypropylmethylcellulose was further added and dissolved to prepare a gelling agent.

Example 19: Aerosol Agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 8 and 60% dimethyl ether gas into a pressure vessel made of aluminum.

Example 20: Aerosol Agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 9 and 60% of a liquefied petroleum gas / dimethyl ether mixed gas into a pressure vessel made of aluminum.

Example 21: Aerosol agent An aerosol agent was prepared by putting 40% of the lotion agent of Example 10 and 60% of dimethyl ether gas into a pressure vessel made of aluminum.

Example 22: 0.5 g of tic agent piroxicam
l-Menthol 3.0g
Tocopherol acetate 0.5g
Light anhydrous silicic acid 4.0g
1,3-butylene glycol 25.0g
Benzyl alcohol 1.0g
Purified water 5.0g
Polysorbate 80 1.0g
Glycerol monostearate 1.0g
Hydroxypropyl methylcellulose 0.5g
Sodium stearate 10.0g
Sodium bisulfite appropriate amount edetate appropriate amount ethanol 100g
After the above components were dissolved by heating, they were filled into a cylindrical container, cooled to room temperature by slow cooling to such an extent that light anhydrous silicic acid did not settle, and solidified to prepare a tic agent.

Example 23: Ointment piroxicam 0.5 g
Glycyrrhetinic acid 0.02g
l-Menthol 3.0g
Tocopherol acetate 0.5g
Light anhydrous silicic acid 10.0g
White petrolatum 20.0g
Dextrin palmitate 15.0g
Dimethylpolysiloxane 0.05g
100g liquid paraffin
After the oil component and the drug were uniformly dissolved or dispersed while heating, light anhydrous silicic acid was added and the mixture was gradually cooled to room temperature while stirring well to prepare an ointment.

  With the formulations shown in the following table, gel agents of Examples and Comparative Examples were produced by ordinary methods.

(Test Example 1) Rat Percutaneous Permeability Test (Method)
Skin was extracted from the left and right sides of the abdominal shaved part of a hairless rat (male, 8 to 10 weeks old) shaved with an electric shaver. After the extracted skin is attached to a horizontal diffusion cell with an average effective area of 0.98 cm ^2, a certain amount of each sample shown in Table 1 is applied to the cell on the donor side, and pH 7.4 phosphate buffer is applied to the cell on the receiver side. 3 mL of the solution was added. Constant temperature water at 37 ° C. was refluxed to the outer layer of the receiver layer, and the receiver liquid was stirred with a stirring bar.

  A fixed amount of the receiver solution was collected over time, and the drug amount was measured by high performance liquid chromatography using piroxicam 255 nm, indomethacin 254 nm, and internal standard substances propyl paraoxybenzoate and heptyl paraoxybenzoate.

  The results of the skin permeability test of the piroxicam formulation are shown in FIG. It was found that the permeability was dramatically increased by adding light anhydrous silicic acid as compared with Comparative Example 1.

  Further, FIG. 2 shows the cumulative permeation amount of piroxicam after 10 hours in Example 1 when the cumulative permeation amount after 10 hours of Comparative Example 1 is 100%. It can be seen that Example 1 increased due to the addition of light silicic anhydride.

  The results of the skin permeability test of the indomethacin preparation are shown in FIG. By blending the light anhydrous silicic acid particles, the skin permeability of indomethacin was dramatically increased in Example 3 as compared with Comparative Example 5.

  In addition, FIG. 4 shows indomethacin cumulative permeation amount after 10 hours in each comparative example and Example 3 when the cumulative permeation amount after 10 hours of Comparative Example 5 is 100%. It can be seen that Example 3 increases due to the addition of the light silicic acid particles.

  The present invention provides an external anti-inflammatory analgesic composition exhibiting excellent effects. More specifically, the present invention provides an external anti-inflammatory analgesic composition that promotes skin permeability of piroxicam or indomethacin and has an excellent anti-inflammatory analgesic effect.

It is the figure which showed the measurement result of the piroxicam accumulated permeation amount of Example 1 and Comparative Example 1, the accumulated permeation amount (μg / cm ² ) on the vertical axis, and time on the horizontal axis (hairless rat n = 3-4) ). It is the figure which showed the measurement result (hairless rat n = 3-4) of the piroxicam accumulation permeation amount of each comparative example and Example 1 when the comparative example 1 was set to 100. It is the figure which showed the measurement result of the indomethacin cumulative permeation amount of Example 3 and Comparative Example 5, and the vertical axis represents the cumulative permeation amount (μg / cm ² ) and the horizontal axis represents time (hairless rat n = 3 to 4). ). It is the figure which showed the measurement result (hairless rat n = 3-4) of indomethacin accumulated permeation amount of each comparative example and Example 5 when the comparative example 5 is set to 100.

Claims (9)

A topical anti-inflammatory analgesic composition comprising a non-steroidal anti-inflammatory analgesic and light anhydrous silicic acid. 2. The external anti-inflammatory analgesic composition according to claim 1, wherein the non-steroidal anti-inflammatory analgesic is piroxicam. 2. The external anti-inflammatory analgesic composition according to claim 1, wherein the non-steroidal anti-inflammatory analgesic is indomethacin. The anti-inflammatory analgesic composition for external use according to claim 1, wherein the compounding amount of the non-steroidal anti-inflammatory analgesic is 0.1 to 20% by mass of the whole preparation. 2. The anti-inflammatory analgesic composition for external use according to claim 1, wherein the blending amount of light silicic acid is 0.1 to 10% by mass of the whole preparation. The external anti-inflammatory analgesic composition according to any one of claims 1 to 5, which is a gel. Selected from the group consisting of carboxyvinyl polymer, alkyl-modified carboxyvinyl polymer, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose or salt thereof, alginic acid or salt thereof, xanthan gum and carrageenan The anti-inflammatory analgesic composition for external use according to claim 6, wherein the composition is gelled by one kind or two or more kinds. A non-steroidal external anti-inflammatory analgesic skin absorption enhancer characterized by comprising light anhydrous silicic acid. An external anti-inflammatory analgesic composition comprising light anhydrous silicic acid, wherein the light anhydrous silicic acid promotes skin absorption of a non-steroidal external anti-inflammatory analgesic.

Images